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We linked four nationwide Swedish population-based registries to identify first-degree family history of breast and ovarian cancer
among breast cancer cases diagnosed between 1991 and 1998 and followed them until death, emigration or end of follow-up in
December 1998. The median follow-up was 36 months. Using Cox proportional hazards models, the hazard ratio of death (HR) due
to breast cancer was estimated. Women with a family history of breast or ovarian cancer (n¼2175, 12.7%) had a nonsignificantly
better prognosis than women without any family history, HR 0.86 (95% CI 0.71–1.05); this appeared unrelated to age at diagnosis
either in the index case or in relative(s) with breast and/or ovarian cancer. Our study shows that prognostic outlook is not worse
among breast cancer patients with family history.
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Family history is a strong risk factor for breast cancer but its
prognostic value has not been clearly established. Few population-
based studies have addressed this issue and the results are
conflicting. Previous investigators have demonstrated family
history to be associated with a significantly longer (Fukutomi
et al, 1993; Malone et al, 1996; Mohammed et al, 1998; Gajalakshmi
et al, 1999) or shorter survival (Slattery et al, 1993). Some studies
found no association between family history and survival
(Hermann et al, 1985; Anderson and Badzioch, 1986; Israeli et al,
1994; Schouten et al, 1997; Russo et al, 2002). Apart from varying
strategies for selection of study population and varying definitions
of family history, insufficient sample sizes might explain the
differences. We have evaluated the impact of a family history of
breast and/or ovarian cancer in first-degree relatives on breast
cancer survival by using large Swedish population-based registries.
PATIENTS AND METHODS
Data sources
All Swedish residents are assigned an individually unique 10-digit
national registration number. This number enables crosslinkage of
various nationwide health data registries. Our study links four
such registries; The Swedish Cancer Register, The Cause of Death
Register, The Multi-Generation Register and The Total Population
Register. The Swedish Cancer Register contains information about
all cancers diagnosed in Sweden since 1958. It maintains a high
degree of completeness due to mandatory reporting by both
clinicians and pathologists/cytologists (Mattsson and Wallgren,
1984; National Board of Health and Welfare, 1996). The register
does not include information about disease stage or treatment.
Established in 1952, the Cause of Death Register provides the date
of death, as well as the underlying and contributory causes of death
of all deceased Swedish residents. The causes of death are classified
according to the International Statistical Classification of Diseases
and Related Health Problems (ICD), version 6–10. The complete-
ness of the classification of the cause of death in the registry is
estimated to exceed 99% (National Board of Health and Welfare,
2001).
The Multi-Generation Register includes all Swedish residents
born after 1931, who were alive in 1960, and all those born
thereafter. It contains links between children and parents through
their national registration numbers. Adoptions and nonbiological
relations are flagged. The register is updated yearly. We used the
31 December 2000 version for the present study (Statistics Sweden,
2001:5). The Total Population Register includes information about
births and deaths in the entire Swedish population since 1968. The
register is updated yearly and kept by the Swedish tax authorities.
The Karolinska Institutet Ethics Committee has reviewed and
approved this study.
Study cohort and family history
In the Swedish Cancer Register, we identified 20468 women born
after 1931, alive in 1960, and diagnosed with primary breast cancer
between 1991 and 1998. Our rationale for the choice of this recent
study period was that for individuals who died between 1991 and
1998, notification of mothers in the Multi-Generation Register has
reached 90% completeness (Statistics Sweden, 2001:5). To obtain
follow-up information, we linked the study cohort to the Cause of
Death Register and the Total Population Register. The breast
cancer cases were followed from the date of breast cancer diagnosis
until the end of the study, 31 December 1998, or the date of death
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yor emigration, whichever occurred first. Breast cancer deaths only
included those where breast cancer was coded as the underlying
cause of death. Linkage of our cohort to the Multi-Generation
Register provided us with information about any first-degree
relatives (parents, siblings or children) of index cases. We
excluded 2729 index patients who were registered as immigrants,
and 158 who had been diagnosed with other cancers prior to their
breast cancer. We could not identify any relatives for 486 index
patients and therefore excluded them. Our cohort thus consisted of
17095 index breast cancer cases. We identified incident cancers
among the relatives of the index cases though rematching with the
Swedish Cancer Register. Our inclusion criteria resulted in a
maximum attained age at diagnosis that was 59 years in 1991 and
66 years in 1998.
Statistical methods
We used Cox proportional hazards models to estimate the hazard
ratio of death due to breast cancer (HR) and 95% confidence
intervals (95% CI) associated with family history. We only
considered family history that was apparent at the time of index
case diagnosis. Analyses were stratified by age at diagnosis (in 5-
year age groups), calendar year (in 5-year intervals) and number of
female first-degree relatives in order to control the interdependent
effects of treatment time trends, age and varying potential of
having a manifested family history of breast and/or ovarian cancer.
We estimated survival during the entire follow-up and separately
during the first 5 and the following years after diagnosis in order to
check the assumption of proportional hazards during follow-up.
By introducing interaction terms in the Cox model, we tested if
there were differences in the effects of family history on prognosis
according to age at diagnosis or follow-up time. All analyses were
performed using SAS procedure PROC PHREG (Version 8.2, SAS
Institute, NC, USA).
RESULTS
Out of the 17095 breast cancer cases we studied, 2175 (about 13%)
had at least one first-degree relative with breast and/or ovarian
cancer (Table 1). In all, 1238 women diagnosed with breast cancer
between 1991 and 1998 died of breast cancer, 112 of who had a
family history of breast and/or ovarian cancer (Table 2). The mean
and median follow-up was 39.6 and 36 months, respectively.
Familial cases had a nonsignificantly better prognosis than
nonfamilial cases (HR¼0.87; 95% CI 0.71–1.05) without any
appreciable difference related to duration of follow-up (Table 2,
Figure 1). Among women who had more than one first-degree
relative with breast or ovarian cancer, the association seemed
particularly pronounced (HR¼0.21; 95% CI 0.03–1.53), although
this estimate was based on small numbers. The age at diagnosis of
the index case or the first-degree relative did not influence the
association between family history and breast cancer prognosis
(Table 2).
DISCUSSION
We show that there is no significant difference in the prognosis of
breast cancer among women with a first-degree relative of breast
or ovarian cancer to cases without family history. The relation was
not convincingly modified by duration of follow-up or age at
diagnosis in the index case or the relative.
This is one of the largest population-based studies of the relation
between family history and breast cancer prognosis published to
date. Through linkage of the Multi-Generation and Cancer
registries by the national registration numbers instead of relying
on reports from the study subjects, we have minimized
misclassification of the factor of main interest, family history.
Ascertainment of family history was based on the number of first-
degree relatives with breast and/or ovarian cancer in the Swedish
Cancer Registry. However, due to chance and the high incidence of
breast cancer, there may be clustering of sporadic breast cancer in
families, giving a spurious impression of familial disease. Indeed,
in our data, frequency of family history does not vary substantially
over age groups (data not shown). Such clustering would have
Table 1 Various aspects of family history of breast and ovarian cancer
among women born after 1931, diagnosed with first breast cancer cases
between 1991 and 1998 (n¼17095)
Number (%)
Family history of breast and/or ovarian cancer
No 14920 (87.2%)
Yes 2175 (12.7%)
Number of FDR
a with breast or ovarian cancer
One relative 2090 (12.2 %)
Two or more 85 (0.5 %)
Family history type
Breast cancer 1824 (10.7 %)
Ovarian cancer 313 (1.8 %)
Both 38 (0.2 %)
Age at diagnosis in FDR
a
Z50 years 1614 (9.4 %)
o50 years 561 (3.3 %)
Sequence of diagnosis in FDRa relative to index case
Before 1883 (11.0 %)
After 292 (1.7 %)
aFDR¼first-degree relative(-s).
Table 2 Hazard ratios (HRs) for breast cancer death comparing women
with and without first-degree family history of breast or ovarian cancer
Family
history Deaths
a Person-years HR 95% CI
Overall
No 1126 50549 1 Ref
Yes 112 6039 0.86 0.71–1.05
FDR age at diagnosis
b
o50 years Yes 43 2299 0.82 0.60–1.12
X50 years Yes 69 3740 0.89 0.70–1.14
Number of FDR with breast or ovarian cancer
b
One Yes 111 5821 0.89 0.73–1.08
Two or more Yes 1 218 0.21 0.03–1.49
Stratified by time period after diagnosis
First 5 years No 1061 45,115 1 Ref
Yes 106 5418 0.86 0.70–1.05
After first 5 years No 65 5434 1 Ref
Yes 6 621 0.94 0.40–2.19
Stratified by index case age at diagnosis
o50 years No 575 23116 1 Ref
Yes 64 3054 0.87 0.67–1.13
X50 years No 551 27433 1 Ref
Yes 48 2985 0.85 0.63–1.15
95% CI¼95 percent confidence interval; HR¼hazard ratio; FDR¼first-degree
relative with breast or ovarian cancer.
aDeaths due to breast cancer.
bCases with first-
degree relatives with breast or ovarian cancer are compared to cases without first-
degree relatives with breast or ovarian cancer.
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degree family history of breast or ovarian cancer. In this regard,
Malone et al (1996) found that women who had a first-degree
family history experienced significantly better prognosis while a
positive second-degree family history was not associated with
survival.
Given the report of a worse prognosis of familial breast cancer
(Slattery et al, 1993), our findings are reassuring. However, there
may be heterogeneity among familial breast cancers. For example,
gene expression pattern has allowed definition of six distinct
breast cancer subclasses (Sorlie et al, 2001). We could not
distinguish such subtypes as we lacked details of gene mutations
such as BRCA1 which can influence survival (Stoppa-Lyonnet et al,
2000).
We also did not have any information about stage of breast
cancer at diagnosis. According to our main hypothesis, breast
cancer arising in women with a genetic predisposition might have
a different, presumably more aggressive, biologic behaviour than
sporadic cancer with a nongenetic aetiology. We pondered whether
stage of disease at diagnosis—or any other prognostic factor—
could be a confounder when prognosis was compared between
familial and sporadic cases. Prevalence of metastases, regional or
distant, is the main determinant of stage in a Swedish setting where
most cancers are diagnosed with a diameter smaller than 20mm
(Sundquist et al, 1999). Since metastatic potential is clearly the
main factor in the causal pathway to prognosis, adjustment for this
factor in our analysis would be inappropriate. However, delayed
clinical diagnosis is another determinant of more advance stage.
Confounding would arise if such delay were more or less common
in patients with a family history. In this situation, adjustment for
stage might eliminate the confounding (provided that stage is
accurately classified) but also conceal the key effect we wanted to
study. We conclude that adjustment for stage is a questionable
approach and that our lack of clinical information is a limited
concern.
Previous studies that have compared the survival between breast
cancer cases with and without family history found inconsistent
results. One reason for the inconsistencies can be varying
definitions of family history. An overly generous definition will
attenuate any true association between familial disease and
prognosis. Where stricter criteria for family history are used,
larger proportions of cases will have a genetic component in their
aetiology, possibly including specific prognostic implications.
Similarly, some investigators identify breast cancer cases in
centres for genetic counselling where women with several breast
cancer deaths in their families may be over-represented. Other
studies have been performed within specific ethnic groups where
inherited disease genes are more prevalent, as among Ashkenazi
Jews (Robson et al, 1999). Another source of variation may be that
some studies investigate overall survival that depends heavily on
age at diagnosis as well as on socioeconomic factors. Moreover,
breast cancer death can occur many years after primary diagnosis
and some studies have a short follow-up time. Finally, chance has a
role in explaining certain differences from previous studies.
In conclusion, our study shows that prognosis is not worse
among familial breast cancer cases overall.
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Figure 1 Kaplan–Meier survival curve. Women who died from other
causes than breast cancer were censored at the time of death.
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